Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME and Bioavailability Study of AG-881 in Healthy Males
NCT03960502Phase 1Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- May 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vorasidenib in glioma, sponsored by Agios Pharmaceuticals. Primary endpoints: Amount of AG-881 Excreted in Urine, Cumulative Amount of AG-881 Excreted in Urine and 9 more. Started May 2019; status: completed.
02
Drugs
vorasidenib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT03960502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03960502.